The short answer
Three randomised controlled trials have tested semaglutide in alcohol use disorder. All reported reductions in craving or heavy drinking against placebo. All were small (48, 50 and 108 participants) and short, running 8 to 26 weeks, so they establish a signal rather than an effect size.
Key facts
- Trial 1
- 48 participants, 9 weeks, weekly injection
- Trial 2
- 50 participants, 8 weeks, oral semaglutide
- Trial 3
- 108 participants, 26 weeks, plus CBT
- Consistent finding
- Reduced craving and heavy drinking days
- Largest trial size
- 108, small by any standard
- Approved for this use
- No, in any jurisdiction
- Key references
- PMID 39937469, PMID 42522065
Why anyone looked
The observation came before the hypothesis. People taking GLP-1 agonists for weight or glucose reported drinking less without intending to, consistently enough that it became a research question rather than an anecdote. That is a weak starting point epistemically (self-report from people undergoing a major metabolic intervention is confounded in obvious ways), which is why randomised trials followed.
The three trials
Hendershot and colleagues reported in JAMA Psychiatry in April 2025 on 48 non-treatment-seeking adults given low-dose weekly semaglutide over nine weeks, finding reduced alcohol consumed in a laboratory self-administration procedure and reduced weekly craving. Schacht and colleagues reported in the American Journal of Psychiatry in July 2026 on 50 people with moderate-to-severe alcohol use disorder given oral semaglutide over eight weeks, finding fewer heavy drinking days, fewer drinks per drinking day and reduced craving. A third trial randomised 108 treatment-seeking patients with comorbid obesity to semaglutide or placebo alongside cognitive behavioural therapy for 26 weeks, again reporting fewer heavy drinking days.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What size and duration mean here
Forty-eight, fifty and one hundred and eight participants are small trials. For comparison, SELECT enrolled 17,604 to establish a cardiovascular outcome. Small trials can establish that an effect exists; they are poorly suited to estimating how large it is, and they are vulnerable to chance findings. Nine weeks, eight weeks and twenty-six weeks are also short relative to a chronic condition where relapse is measured over years.
The populations were not the same
This matters more than it looks. The first trial enrolled non-treatment-seeking participants, people not currently trying to stop drinking. That is a standard early-phase design but a very different group from people in treatment. The third enrolled treatment-seeking patients receiving cognitive behavioural therapy alongside the drug. A finding in one population does not transfer automatically to the other, and the third design cannot separate the drug's contribution from the therapy's beyond what the placebo arm captures.
What the meta-analysis adds
A systematic review and meta-analysis in eClinicalMedicine in December 2025 pooled effects of GLP-1 receptor agonists on alcohol consumption. Pooling small trials increases precision but cannot fix their common limitations. If every included trial is short and small, the pooled result is a more precise estimate of a short-term effect in small samples.
Regulatory position
No GLP-1 agonist is approved for alcohol use disorder in any jurisdiction. This is an active research question with a consistent early signal, not an established indication, and material supplied for laboratory research has no relationship to it whatsoever.
Frequently asked questions
Does semaglutide treat alcohol use disorder?
It is not approved for that use anywhere. Three small randomised trials report reductions in craving and heavy drinking, which establishes a signal rather than an established treatment.
How strong is the evidence?
Consistent in direction across three trials, but all were small (48, 50 and 108 participants) and short. Consistency across small studies is encouraging, not conclusive.
Why would a metabolic drug affect drinking?
GLP-1 receptors are expressed in brain regions involved in reward processing as well as in appetite regulation, which is the leading mechanistic hypothesis.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedHendershot CS et al., Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry 2025 (PMID 39937469)pubmed.ncbi.nlm.nih.gov
- PubMedSchacht JP et al., Oral Semaglutide for Alcohol Use Disorder. Am J Psychiatry 2026 (PMID 42522065)pubmed.ncbi.nlm.nih.gov
- PubMedEshraghi R et al., GLP-1 receptor agonists and alcohol consumption: systematic review and meta-analysis. eClinicalMedicine 2025 (PMID 41324012)pubmed.ncbi.nlm.nih.gov
- RefNIH: Adding weekly GLP-1 to cognitive behavioural therapy further reduces heavy drinkingnih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- SURMOUNT-OSA: Tirzepatide in Obstructive Sleep ApnoeaTirzepatide reduced apnoea-hypopnoea index by 27.4 events per hour at 52 weeks against 4.8 on placebo. The first incretin approved for a non-metabolic use.
- Why GLP-1 Receptors Turn Up in Reward ResearchGLP-1 receptors are expressed in mesolimbic reward circuitry, not only in appetite regions. That expression is the mechanistic basis for the craving findings.
- Why GLP-1 Drugs Matter Before AnaesthesiaDelayed gastric emptying means a fasted patient on a GLP-1 may still have stomach contents. Ultrasound studies, and why this is a mechanism-linked risk.
- GLP-1 Gastrointestinal Safety SignalsGastroparesis, pancreatitis and bowel obstruction have all been raised as GLP-1 signals. What the comparative cohort data shows, and how the compounds differ.
- How to Read a Pharmacovigilance SignalA reporting odds ratio of 19 does not mean a nineteen-fold risk. What FAERS disproportionality measures actually mean, and why they are so often misreported.